Publicaciones Similares
Brazilian Health System
Guarantees universal access to health and finances the system through taxes through the Unified Health System (SUS) and a private sector.
Orphan drugs in Latin America: the case of eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome
Eculizumab It has been used in the treatment of orphan diseases, such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), neuromyelitis optica spectrum disorder (NMOSD) and myasthenia gravis
Health System in Argentina
To ensure compliance with area policies for the promotion, preservation, and recovery of the population’s health, strengthening the balance between users, providers, and financiers, in conditions of free
competition, transparency, economic efficiency, and social equity.
Health System in Ecuador
The Ministry of Public Health (MSP) offers health care services to the entire population.
What is the inflation reduction act?
An In-Depth Examination of the Inflation Reduction Act: Unraveling its Purpose, Goals, and Impact on the Pharmaceutical Sector. Delve into the intricacies of this legislative initiative, understanding its imperative role in mitigating inflationary pressures. Navigate through the refined landscape of the pharmaceutical market, appreciating the nuanced changes implemented to fortify economic stability and foster enduring industry prosperity.
Oppotunities for orphan drugs in Latin America
There are ample opportunities for the entry of orphan drugs into the region. The size of the Latin American orphan drug market was USD 14.17 billion in 2021 and it is estimated that it will increase by 7.38% by 2026. Based on the type of drug, the biological sector dominates the orphan drug market for Latin America